Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 2/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615093 | 0.87 | ACP1 (0.42) | PDE5ALIMK1 | |
| SCHEMBL3618689 | 0.87 | PTGS2 (0.42) | PDE5ALIMK1VNN1HTT | |
| SCHEMBL3609325 | 0.86 | CLK4 (0.44) | PDE5ALIMK1CCNCCDK8MEN1 | |
| SCHEMBL11888533 | 0.85 | PDE5A (0.55) | PDE5ANPC1VNN1HTT | |
| SCHEMBL3604672 | 0.84 | PDE5A (0.45) | PDE5ANPC1VNN1HTTMEN1 | |
| SCHEMBL11888473 | 0.82 | EGFR (0.47) | PDE5ANPC1VNN1HTTCCNC | |
| SCHEMBL3616168 | 0.82 | PDE5A (0.43) | PDE5ANPC1 | |
| SCHEMBL3618910 | 0.81 | VNN1 (0.47) | PDE5ANPC1VNN1 | |
| SCHEMBL3608487 | 0.79 | PDE5A (0.42) | SRCPDE5ANPC1VNN1HTT | |
| SCHEMBL3608480 | 0.79 | PDE5A (0.42) | SRCPDE5ANPC1VNN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518964-B2 | Tricyclic compounds useful as inhibitors of kinases | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518964-B2 | Tricyclic compounds useful as inhibitors of kinases | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518964-B2 | Tricyclic compounds useful as inhibitors of kinases | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1954290-B1 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | MERCK SHARP & DOHME (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| EP-1954290-A2 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007061764-A2 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | JAK2, JAK3, JAK1 | SRC 253/4885PDE5A 4133/4885LIMK1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.